{"created":"2023-05-15T08:48:51.352033+00:00","id":304,"links":{},"metadata":{"_buckets":{"deposit":"e7d3f44e-7d75-45d5-9f76-add1e4974619"},"_deposit":{"created_by":4,"id":"304","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"304"},"status":"published"},"_oai":{"id":"oai:kawasakigakuen.repo.nii.ac.jp:00000304","sets":["33:34"]},"author_link":["372","314","376"],"control_number":"304","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"19","bibliographicPageStart":"12","bibliographicVolumeNumber":"1","bibliographic_titles":[{"bibliographic_title":"COGNITION & REHABILITATION","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Alzheimer disease (AD) is the most common type of dementia and may account for 60 - 70% of dementia cases. Senile plaques are a hallmark of AD, and their major constituent is amyloid β-protein (Aβ) 42. Aβ is produced via endoproteolysis by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves β-amyloid precursor protein at the extracellular domain, followed by cleavages by presenilin/γ-secretase. Aβ accumulation in the brain is thought to occur decades before disease onset, and pathological changes such as synaptic dysfunction and tau accumulation gradually proceed. Most candidates for disease-modifying therapy (DMT) for AD have targeted either inhibition of Aβ generation with secretase inhibitors or removal of produced and aggregated Aβ with anti-Aβ antibodies. None of them has been approved for clinical practice. Moreover, application of BACE inhibitors and γ-secretase inhibitors in several clinical studies caused paradoxical cognitive impairment. However, early AD patients treated with aducanumab, a monoclonal anti-Aβ antibody, showed a significant reduction in cognitive decline and its clinical use is awaiting approval by the FDA in 2020. In this review, we present a brief summary of DMTs that target Aβ and perspectives for future AD therapy.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容種別","attribute_value_mlt":[{"subitem_description":"Review Article","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"大阪河﨑リハビリテーション大学","subitem_publisher_language":"ja"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2436-1097","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shinji TAGAMI","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Masatoshi TAKEDA","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Masayasu OKOCHI","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-08-10"}],"displaytype":"detail","filename":"C 1-012-019.pdf","filesize":[{"value":"279.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"C 1-012-019","url":"https://kawasakigakuen.repo.nii.ac.jp/record/304/files/C 1-012-019.pdf"},"version_id":"9e5d57e5-b225-4738-baa0-d84ca9af89a4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Alzheimer disease","subitem_subject_scheme":"Other"},{"subitem_subject":"amyloid β-protein","subitem_subject_scheme":"Other"},{"subitem_subject":"γ-secretase inhibitors","subitem_subject_scheme":"Other"},{"subitem_subject":"BACE inhibitors","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-Aβ antibodies","subitem_subject_scheme":"Other"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"other","resourceuri":"http://purl.org/coar/resource_type/c_1843"}]},"item_title":"Clinical trials for Alzheimer disease and perspectives","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical trials for Alzheimer disease and perspectives","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"4","path":["34"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-08-10"},"publish_date":"2021-08-10","publish_status":"0","recid":"304","relation_version_is_last":true,"title":["Clinical trials for Alzheimer disease and perspectives"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-10-02T00:51:07.779041+00:00"}